MedTrace Logo

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

NCT03831607 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-03-07

No results posted yet for this study

Summary

To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

KHK7791

KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-27
Primary Completion
2019-11-26
Completion
2019-11-26

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831607 on ClinicalTrials.gov